陈芳超,刘金泳,朱秀梅
CHEN Fangchao,LIU Jinyong,ZHU Xiumei

• 1:广州市第一人民医院南沙医院药学科

摘要(Abstract)：

目的对一例使用双联抗血小板引起皮肤瘀斑的病例进行分析,探讨DAPT的药学监护点,为临床药师深入参与临床提供切入点。方法对患者进行药学监护,查阅文献资料,从药物、患者两方面分析出现不良反应事件的原因。结果患者调整DAPT治疗方案后,患者瘀斑较前消退。结论临床药师开展药学监护,可促进临床安全、合理地使用药物。
OBJECTIVE To analysis a case of skin ecchymosis caused by dual antiplatelet therapy( DAPT),so as to probe into the pharmaceutical care point of DAPT,and provide breakthrough point for clinical pharmacists to participate in clinical. METHODS Pharmaceutical care for patients was delivered,and the causes of adverse events from the drug and patients two aspects were analyzed by searching literature. RESULTS Ecchymosis subsided after adjusting the treatment plan. CONCLUSION Clinical pharmacists to carry out pharmaceutical care,can promote clinical safety and rational using of drugs.

关键词(KeyWords)： 双联抗血小板;皮肤瘀斑;案例分析
dual antiplatelet therapy;skin ecchymosis;case analysis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈芳超,刘金泳,朱秀梅
CHEN Fangchao,LIU Jinyong,ZHU Xiumei

参考文献(References)：

• [1]郭建华,闰洪娟,等.老年冠心病双联抗血小板治疗中出血事件的相关危险因素分析[J].大连医科大学学报,2016,38(3):250-253.
• [2]中华医学会老年医学分会,《中华老年医学杂志》编辑委员会.老年人质子泵抑制剂合理应用专家共识[J].中华老年医学杂志,2015,34(10):1045-1052.
• [3]国家食品药品监督管理总局(CFDA).警惕质子泵抑制剂的骨折、低镁血症风险以及与氯吡格雷的相互作用[J].中国药房,2013,24(25):2400.
• [4]Bowry A D,Brookhart M A,and Choudhry N K.Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events[J].American Journal of Cardiology,2008,101(7):960-966.
• [5]Steven R Steinhubl,Deepak L Bhatt,Danielle M Brennan,et al.Aspirin to Prevent Cardiovascular Disease:The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding[J].Ann Intern Med,2009,150(6):379-386.
• [6]Tesse C,Leunissen,Paul W A,et al.The use of platelet reactivity testing in patients on antiplatelet therapy forprediction of bleeding events after cardiac surgery[J].Vascular Pharmacology,2015,77(2):19-27.
• [7]FDA Drug Safety Communication:reduced effectiveness of Plavix(clopidogrel)in patients who are poor metabolizers of the drug[EB/OL].http://www.fda.gov/Drugs/Drug Safety/Postmarket Drug SafetyInfor mationfor Patientsand Providers/ucm190836.htm.
• [8]K Mátyás,T Marcello,JFE Man,et al.Renal function and outcomes in acute coronary syndrome:impact of clopidogrel[J].European Journal of Cardiovascular Prevention&Rehabilitation,2007,14(1):312-318.
• [9]P Best,S R Steinhubl,P B Berger.The efficacy and safety of shortand long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease:Results from the Clopidogrel for the Reduction of Events During Observation(CREDO)Trial[J].American Heart Journal,2008,155(4):687-693.
• [10]Angiolillo D J,Bernardo E,Capodanno D,et al.Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy[J].Journal of the American College of Cardiology,2010,55(11):1139-1146.